不同血药浓度FK506在肝移植术后应用的比较

Comparative study on the application of the different concentrations of FK506 after liver transplantation

目的总结肝脏移植术后应用免疫抑制药他克莫司(FK506)的经验。方法回顾性分析52例乙肝后肝硬化失代偿期肝移植患者的临床资料,依据术后应用FK506的浓度分为两组,观察其两组的术后存活率、移植肝功能及并发症发生情况。结果术后1年人/肝存活率、急性排斥反应及HBV再感染发生率,两组差异无统计学意义,肝功能在术后3、6个月两组之间差异有统计学意义,其余时间点差异无统计学意义,而术后肺部感染、新发糖尿病及高血脂发生率情况,两组差异有统计学意义。结论肝移植术后应用低剂量FK506更安全有效,术后一些并发症的发生和该药物的浓度有一定的相关性。

Objective To sum up the clinical experience of immunosuppression agent FK506 in patients after liver transplantation.Methods Fifty-two cases of liver cirrhosis caused by hepatitis B after liver trans-plantation were analyzed retrospectively and divided into two groups：low blood concentration group and common blood concentration group,based on the concentration of FK506,then the difference of graft survival rate,liver function and some complications were observed between the two groups.Results There were no significant statistical differences in one year survival rate,the frequency of acute rejection and HBV rinfection.There was a significant difference between the two group in liver function after 3 and 6 months,no statistically significant difference in the rest of the time.Differences between the two groups were significant in lung infections,diabetes and the incidence of high blood cholesterol.Conclusion It is more safer and effective to use low dose FK506 in patients after liver transplantation,and the occurrence of some post-operative complications maybe has definite correlation with the blood concentration of the drug.